Lemken Marie-Luise, Wybranietz Wolfgang-A, Schmidt Ulrike, Graepler Florian, Armeanu Sorin, Bitzer Michael, Lauer Ulrich-M
Department of Internal Medicine I, Medical University Clinic Tubingen, Otfried-Muller-Str. 10, D-72076 Tubingen, Germany.
World J Gastroenterol. 2005 Sep 14;11(34):5295-302. doi: 10.3748/wjg.v11.i34.5295.
To generate and characterize the synthetic transcriptional control units for transcriptional targeting of the liver, thereby compensating for the lack of specificity of currently available gene therapeutic vector systems.
Synthetic transcriptional control unit constructs were generated and analyzed for transcriptional activities in different cell types by FACS quantification, semi-quantitative RT-PCR, and Western blotting.
A new bifunctionally-enhanced green fluorescent protein (EGFP)/neo(r) fusion gene cassette was generated, and could flexibly be used both for transcript quantification and for selection of stable cell clones. Then, numerous synthetic transcriptional control units consisting of a minimal promoter linked to "naturally" derived composite enhancer elements from liver-specific expressed genes or binding sites of liver-specific transcription factors were inserted upstream of this reporter cassette. Following liposome-mediated transfection, EGFP reporter protein quantification by FACS analysis identified constructs encoding multimerized composite elements of the apolipoprotein B100 (ApoB) promoter or the ornithin transcarbamoylase (OTC) enhancer to exhibit maximum transcriptional activities in liver originating cell lines, but only background levels in non-liver originating cell lines. In contrast, constructs encoding only singular binding sites of liver-specific transcription factors, namely hepatocyte nuclear factor (HNF)1, HNF3, HNF4, HNF5, or CAAT/enhancer binding protein (C/EBP) only achieved background levels of EGFP expression. Finally, both semi-quantitative RT-PCR and Western blotting analysis of Hep3B cells demonstrated maximum transcriptional activities for a multimeric 4xApoB cassette construct, which fully complied with the data obtained by initial FACS analysis.
Synthetic transcriptional control unit constructs not only exhibit a superb degree of structural compactness, but also provide new means for liver-directed expression of therapeutic genes.
构建并鉴定用于肝脏转录靶向的合成转录调控单元,以弥补现有基因治疗载体系统缺乏特异性的不足。
构建合成转录调控单元构建体,并通过荧光激活细胞分选(FACS)定量、半定量逆转录-聚合酶链反应(RT-PCR)和蛋白质免疫印迹法分析其在不同细胞类型中的转录活性。
构建了一个新的双功能增强型绿色荧光蛋白(EGFP)/新霉素抗性(neo(r))融合基因盒,它可灵活用于转录定量和稳定细胞克隆的筛选。然后,将许多由最小启动子与来自肝脏特异性表达基因的“天然”复合增强子元件或肝脏特异性转录因子结合位点相连组成的合成转录调控单元插入该报告基因盒的上游。脂质体介导转染后,通过FACS分析对EGFP报告蛋白进行定量,结果显示,编码载脂蛋白B100(ApoB)启动子或鸟氨酸转氨甲酰酶(OTC)增强子多聚化复合元件的构建体在源自肝脏的细胞系中表现出最大转录活性,而在非源自肝脏的细胞系中仅为背景水平。相反,仅编码肝脏特异性转录因子单个结合位点的构建体,即肝细胞核因子(HNF)1、HNF3、HNF4、HNF5或CCAAT/增强子结合蛋白(C/EBP),仅达到EGFP表达的背景水平。最后,对Hep3B细胞进行的半定量RT-PCR和蛋白质免疫印迹分析均显示,多聚化的4xApoB盒构建体具有最大转录活性,这与最初FACS分析得到的数据完全一致。
合成转录调控单元构建体不仅具有高度的结构紧凑性,还为治疗性基因的肝脏定向表达提供了新方法。